SAM
DNLI icon

Stenahm Asset Management’s Denali Therapeutics DNLI Stock Holding History

Stenahm Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-45,000
Closed -$3.53M – 28
2021
Q2 		$3.53M Buy
+45,000
New +$2.78M 2.16% 18

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stenahm Asset Management's DNLI Position: Q3 2021 in Review

Stenahm Asset Management sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 45,000 shares — an estimated $3.53M sold.

Stenahm Asset Management first reported a position in DNLI in Q2 2021 and held it in 1 quarter. The position peaked at $3.53M in Q2 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Stenahm Asset Management reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Stenahm Asset Management sold 45,000 Denali Therapeutics shares in Q3 2021, an estimated $3.53M.
  • Stenahm Asset Management first reported a position in Denali Therapeutics in Q2 2021 and held it in 1 quarter.
  • Stenahm Asset Management's Denali Therapeutics position peaked at $3.53M in Q2 2021.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Stenahm Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.